Lignes directrices provisoires
26 janvier 2020
Ce document propose des listes de contrôle élaborées par l’OMS en matière de communication sur les risques et de participation communautaire (RCCE) pour la préparation et les premières ripostes face au nouveau coronavirus 2019 (2019-nCoV) r...écemment identifié à Wuhan, dans la province du Hubei, en Chine. Il a pour objectif de donner aux pays des conseils pratiques pour la mise en œuvre de stratégies efficaces en matière de RCCE qui contribueront à protéger la santé publique lors des premières phases de la riposte face à un nCoV. Ce document inclut des objectifs et des actions de RCCE recommandés pour les pays qui se préparent à faire face à des cas de nCoV et pour ceux qui ont déjà des cas confirmés d’infection par le 2019-nCoV.
more
This guidance note identifies strategic action for policy-makers and managers at the national, subnational and facility level to address these different challenges.
This document has been developed for the WHO Regional Office for the Eastern Mediterranean to establish a regional plan of action to support the countries of the Region to rapidly accelerate the scaling up of their capacities for the prevention and early detection of, and ... rapid response to, coronavirus disease 2019 (COVID-19), as required under the International Health Regulations (IHR 2005). The regional plan is aligned with the WHO global 2019 novel coronavirus strategic preparedness and response plan, but tailored to the regional context.
more
Internally displaced persons (IDPs), refugees, migrants and returnees constitute a sizeable population in the WHO Eastern Mediterranean Region. There were 12 million refugees (half are Palestinians) and 13 million IDPs in the Region as of 2018. These populations are often vul...nerable to poor health due to the conditions they live in and limited access to needed quality health care. In addition, those who can access care, are often faced with financial hardship. There are also 46 million professionals and low-income labour migrants in the Region (of which 22 million are from the Region), with differential access to health services and varied health coverage schemes
more
Five months after the beginning of the desert locust upsurge in the Greater Horn of Africa and Yemen, and four months since the launch of the response plan (24 January 2020) a total of USD 130 million have been mobilized in the region.
As described in the recently published Food and Agriculture Org...anization of the United Nations (FAO) quarterly report (January to April 2020), a lot has been achieved already, thanks to generous contributions from resource partners and affected governments.
But bringing a desert locust upsurge under control and mitigating its impact on livelihoods and food security requires a prolonged effort and numerous factors could influence the duration and magnitude of the problem, including the widespread presence of COVID-19.
more
Migrants in Central Asia and the Russian Federation, have been among the most severely impacted by the COVID-19 pandemic.
In the short term, IOM aims at providing support to migrants who are stranded in countries of destination. In addition, IOM will focus its efforts on addressing data gaps, enhan...cing national and community preparedness, response and recovery efforts, ensuring that affected people have access to basic services, commodities and protection as well as mitigating the socioeconomic impact of COVID-19.
more
While much progress has been achieved over the past year, the Region of the Americas has stubbornly remained the epicenter of the COVID-19 pandemic. PAHO is launching its 2021 COVID-19 Response Strategy and Donor Appeal to continue supporting Latin American and Caribbean countries and territories i...n their fight against COVID-19. This document outlines PAHO’s regional strategy for the year 2021 to sustain and scale-up the response to COVID‑19 pandemic in the Americas, suppress the community transmission of the virus and mitigate the longer-term health impact of the pandemic.
US$ 239 million is needed to support critical response efforts in the Americas between 1 January and 31 December 2021
more
Vatican lays out 20 points for a universal and fair destination of vaccines, for a fairer and healthier world
This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up...date this review and corresponding recommendations as new evidence becomes available.
more
Reseña normativa de la OMS:
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more